Anzeige
Mehr »
Dienstag, 22.07.2025 - Börsentäglich über 12.000 News
Alarm am Metallmarkt: Kupfer unter Strom: USA rüsten sich - was das für Anleger bedeutet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W50M | ISIN: US31189P1021 | Ticker-Symbol: F6T
Tradegate
21.07.25 | 21:29
0,995 Euro
+1,86 % +0,018
1-Jahres-Chart
FATE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
FATE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,9701,01021.07.
0,9650,99421.07.

Aktuelle News zur FATE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.07.Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)97SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...
► Artikel lesen
FATE THERAPEUTICS Aktie jetzt für 0€ handeln
02.07.H.C. Wainwright behält Neutral-Rating für Fate Therapeutics bei 5 US-Dollar bei3
02.07.H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $54
12.06.Needham maintains hold on Fate Therapeutics stock despite lupus data5
11.06.Kursziel für Fate Therapeutics von BofA auf 2,20 US-Dollar gesenkt nach SLE-Daten19
11.06.Fate Therapeutics price target lowered to $2.20 by BofA on SLE data4
11.06.Fate Therapeutics, Inc.: Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress365All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up...
► Artikel lesen
04.06.FATE THERAPEUTICS INC - S-8, Securities to be offered to employees in employee benefit plans2
30.05.FATE THERAPEUTICS INC - 8-K, Current Report3
30.05.Fate Therapeutics beruft neues Vorstandsmitglied16
30.05.Fate Therapeutics appoints new board member1
30.05.Fate Therapeutics, Inc.: Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors1
29.05.Fate Therapeutics to present lupus treatment data at EULAR 20253
29.05.Fate Therapeutics, Inc.: Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress3
14.05.Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus5
14.05.Baird cuts Fate Therapeutics stock target to $4, keeps neutral rating2
13.05.Fate Therapeutics, Inc.: Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates201Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June ...
► Artikel lesen
13.05.FATE THERAPEUTICS INC - 8-K, Current Report1
02.05.Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)118SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...
► Artikel lesen
29.04.Fate Therapeutics, Inc.: Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting3
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2